Advertisement

Reactions Weekly

, Volume 1733, Issue 1, pp 60–60 | Cite as

Apixaban/dabigatran etexilate/rivaroxaban

Bleeding and haematomas: 12 case reports
Case report
  • 17 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a single centre, retrospective study (conducted between May 2011 and April 2017) of 64 patients, 12 patients [ages and sexes not stated] were described, who developed bleeding or haematomas following direct-acting oral anticoagulant (DOAC) treatment with apixaban, rivaroxaban or dabigatran etexilate [dabigatran; dosages and duration of treatments to reactions onset not stated; not all outcomes stated].

A patient, who had atrial fibrillation, received DOAC treatment with dabigatran etexilate. Subsequently, the patient developed DOAC-related major bleeding. The patient received an off-label treatment with factor VIII inhibitor bypassing fraction 6.3 units/kg to reverse the effect of anticoagulant.

A patient, who had chronic deep vein thrombosis and pulmonary embolism, received...

Reference

  1. Dager WE, et al. Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. Thrombosis Research 173: 71-76, Jan 2019. Available from: URL: http://doi.org/10.1016/j.thromres.2018.11.009 - USACrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations